Biogen Inc. (BIIB)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
Pre-Market:
| Previous Close | 201.99 |
| Open | 201.21 |
| Bid | 202.43 x 300 |
| Ask | 202.54 x 100 |
| Day's Range | 198.11 - 205.36 |
| 52 Week Range | 189.44 - 319.76 |
| Volume | |
| Avg. Volume | 1,260,329 |
| Market Cap | 29.478B |
| Beta (5Y Monthly) | -0.01 |
| PE Ratio (TTM) | 25.31 |
| EPS (TTM) | 8.00 |
| Earnings Date | Jul 23, 2024 - Jul 29, 2024 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 287.48 |
GuruFocus.comDecoding Biogen Inc (BIIB): A Strategic SWOT Insight
Insightful Analysis of Biogen Inc's Financials and Strategic Positioning
GlobeNewswireBiogen Receives Positive CHMP Opinion for TOFIDENCE™ (tocilizumab), a Biosimilar Referencing ROACTEMRA®
CHMP positive opinion is based on a robust analytical, non-clinical and clinical data package comparing TOFIDENCE™ to the reference product ROACTEMRA® CAMBRIDGE, Mass., April 25, 2024 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted a positive opinion for TOFIDENCE™ (tocilizumab), a biosimilar monoclonal antibody referencing ROACTEMRA®1. The intravenous formulation of TOFID
ZacksBiotech Stock Roundup: BIIB, BMY's Q1 Earnings, INCY's Acquisition & Updates from VRTX
Biogen (BIIB) and Bristol Myers (BMY) are in focus following Q1 earnings announcement.
© 2024 Yahoo. All rights reserved.